Biggest and Best Product Pipeline of all Biotechs out there with less than $300 M Market-Cap ! Take a Look
The Market Cap of $29 M is really a Big Joke . The Product Pipeline is Super Fantastic and the Burn-rate of around $1.5 M a Year a very low . The Only issue here is just the OTC-listing because many investors avoid OTC stocks but this one is really A MUST HAVE . This Goldmine should trading around $4-5 by now instead of the laughable .57 pennies .Im very sure that once this sleeping giant awake then it will move very fast like ACAD or SNTS and this stock is better than these Biotechs.
Product Application Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- Submit NDA in March 2013
INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
The company will get noticed when they can prove that they can take their FDA approvals and make decent cash on them while keeping burn rate low. Honestly, I think the commercialization of the pet medicine in "film" form would probably be a much larger money maker than some of the things they are pursuing with greater priority.